Pular para o conteúdo
Merck

[Rare cause for severe hypertriglyceridemia - case 9/2013].

Deutsche medizinische Wochenschrift (1946) (2013-11-14)
Sabine Kahl, Michael Roden, Klaus Mörike, Karsten Müssig
RESUMO

We report on a 48-year-old female patient with recently developed severe hypertriglyceridemia. Medical history was remarkable for breast cancer with breast-preserving surgery and chemoradiotherapy. The patient has been treated with 20 mg tamoxifen per day for three months. Laboratory results showed hypertriglyeridemia, hypercholesterolemia and lowered HDL-cholesterol. Findings were consistent with a drug-induced hypertriglyceridemia caused by anti-estrogenic therapy with tamoxifen. After consulting the patient's gynaecologist, we discontinued tamoxifen treatment. Thereupon, triglyceride levels fell consistently. There were no signs of pancreatitis, serum amylase and lipase were in the normal range. Patients with pre-diagnosed metabolic disorders, especially dyslipidemia and type 2 diabetes, should undergo regular controls of serum triglycerides during tamoxifen treatment. Also, one should keep in mind that a subacute, severe rise in serum triglyceride levels may be caused, in rare cases, by tamoxifen treatment.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Tamoxifeno, ≥99%
Sigma-Aldrich
Tamoxifen citrate salt, ≥99%
Tamoxifen citrate for performance test, European Pharmacopoeia (EP) Reference Standard
Tamoxifen citrate, European Pharmacopoeia (EP) Reference Standard